微封装的抗氧化剂史蒂维亚分离物增强乳清蛋白质,并增强其抗糖尿病活性
Cynthia Letícia S Cabeça1,2, Natani Caroline Nogueira1,2, Maria Rosa T Zorzenon1,2
1Postgraduate Program in Biochemistry, Biochemistry Department, Biological Sciences Center, State University of Maringá (UEM), Maringá - Paraná, Brazil, Av. Colombo, 5790 - Jardim Universitário, Maringá, Paraná CEP: 87020-900 Brazil.
Journal of food science and technology
|June 5, 2023
概括
这项研究用微封装的Stevia rebaudiana强化了乳清蛋白,显示出显著的抗氧化和抗糖尿病潜力. 增强的补充剂显示出良好的感官接受,提供了一个有前途的功能性食品成分.
科学领域:
- 食品科学与技术 食品科学与技术
- 营养保健品 营养保健品
- 生物化学 生物化学
背景情况:
- 乳清蛋白是一种受欢迎的补充剂,但其功能性质可以得到增强.
- 甜 (Stevia rebaudiana) 提供了天然的甜味和潜在的健康益处,包括抗氧化特性.
- 微封装可以提高生物活性化合物的稳定性和生物可用性.
研究的目的:
- 用小囊成份的Stevia rebaudiana来强化乳清蛋白.
- 为了在体外评估强化乳清蛋白的抗氧化和抗糖尿病潜力.
- 评估新型补充剂的可溶性,稳定性和感官接受度.
主要方法:
- 使用马尔托德克斯来微封装 Stevia rebaudiana 分数.
- 乳清蛋白,甜粉和强化产品的特征.
- 在体外测定抗氧化活性,酶抑制 (α-氨基酶,α-葡萄糖酶),溶解性,稳定性和体外消化.
- 常规消费者对乳清蛋白和豆产品的感官评估.
主要成果:
- 微封装的斯蒂维亚分片表现出抗氧化和抗糖尿病能力.
- 强化乳清蛋白显示显著抑制α-氨酶和α-葡萄糖酶酶.
- 微封装成份显示出更好的溶解性和稳定性,包括在体外消化过程中.
- 补充剂配方每100克乳清蛋白中含有1.6%的微封装牛奶,获得了良好的感官接受度.
结论:
- 用微封装的Stevia rebaudiana强化乳清蛋白增强其抗氧化和抗糖尿病特性.
- 开发的补充剂是稳定的,生物可用,和感官可接受.
- 这种强化乳清蛋白代表了对健康意识的消费者来说是一个有前途的功能性食品成分.
相关概念视频
Insulin: Biosynthesis, Chemistry, and Preparation
443
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
443
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
219
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
219
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K


